摘要
目的评价替加环素与头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌的临床疗效。方法重症监护病房(ICU)收治的60例感染泛耐药鲍曼不动杆菌的患者随机分为研究组(n=30)和对照组(n=30),分别给予替加环素+头孢哌酮/舒巴坦和单纯头孢哌酮/舒巴坦治疗,疗程2周。比较两组的临床疗效、细菌清除率、白细胞(WBC)计数、C反应蛋白(CRP)和急性生理与慢性健康评分(APACHEⅡ)。结果研究组总有效率为83.33%(25/30),对照组为50.00%(15/30);研究组细菌清除率为56.67%(17/30),对照组为33.33%(10/30);两组治疗后的APACHEⅡ评分明显增加,WBC计数和CRP都明显降低。治疗后两组三项指标比较差异均具有统计学意义(t=3.852、5.167、4.221,P<0.05)。结论替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌能明显提高临床疗效和细菌清除率,优于单独使用头孢哌酮/舒巴坦。
Objective To evaluate the clinical efficacy of tigecycline combined with cefperazone-sulbactam in treatment of pan-resistant Acinetobacter baumannii.Methods 60 patients infected with pan-drug resistant Acinetobacter baumannii admitted in intensive care unit(ICU)were randomly divided into the study group or control group,who were given tigecycline + cefperazone/sulbactam or cefperazone/sulbactam alone for 2weeks respectively.The clinical efficacy,bacterial clearance rate,white blood cell(WBC)count,C-reactive protein(CRP)and acute physiology and chronic health evaluation(APACHE Ⅱ)were evaluated and compared between the two groups.Results The total efficiency rate was 83.33%(25/30)in study group,obviously higher than the 50.00%(15/30)in control group(P〈0.05).The bacterial clearance rate was56.67%(17/30)in study group,higher than the 33.33%(10/30)in control group(P〈0.05).The APACHE Ⅱ scores significantly increased while WBC count and CRP significantly decreased in both groups(t=3.852,t=5.167,t=4.221;P〈0.05).Conclusion The combination therapy of tigecycline plus cefperazone/sulbactam can obviously improve the clinical efficacy and bacterial clearance rate in treatment of pan-resistant Acinetobacter baumannii,superior to cefperazone/sulbactam alone.
出处
《中国微生态学杂志》
CAS
CSCD
2016年第2期181-184,共4页
Chinese Journal of Microecology
基金
浙江省自然科学基金(Y12H190008)
关键词
替加环素
泛耐药
鲍曼不动杆菌
Tigecycline
Pan-drug resistance
Acinetobacter baumannii